Pharmtrace Klinische Entwicklung

Pharmtrace is a niche, service-oriented CRO with a strong focus on the complex domain of imaging in clinical trials, including studies involving radiopharmaceuticals and radioactive devices. It has built a proprietary technology platform, ERICA, to address the operational challenges of image management and independent reads, serving a global clientele of pharmaceutical, biotech, and academic sponsors. The company is privately held, has grown organically through retained earnings and repeat business since 2006, and possesses significant regulatory experience with agencies like the FDA and EMA. Its value proposition lies in combining specialized therapeutic area expertise with a scalable technology solution for imaging-centric clinical development.

Proprietary, cloud-enabled, GCP-compliant image management platform named ERICA (Electronic Read and Independent Case Assessment). It supports all imaging-related workflows for clinical trials, including image collection, QC, independent reader management, and analysis.

Pharmtrace competes in the imaging CRO segment against large global CROs (e.g., ICON, Labcorp, Parexel) that have dedicated imaging divisions, as well as other niche imaging-focused service providers. Its differentiation lies in its deep specialization in radiopharmaceuticals/radioactive devices, its proprietary ERICA platform, and its agile, expert-driven service model as a private company.